Matches in SemOpenAlex for { <https://semopenalex.org/work/W2436692906> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2436692906 endingPage "45" @default.
- W2436692906 startingPage "539" @default.
- W2436692906 abstract "As a result of medical progress each year numerous new therapies are introduced to the medical community, and each of them must prove its usefulness in two arenas. Firstly, does the new therapy improve outcomes relative to conventional therapy? If this test is passed, the second question is: are the improved outcomes worth the extra costs? Controlled clinical trials answer the first question and economic analysis, the second. The CARPIE-Study has proven, that Clopidogrel, a new antiplatelet drug, was superior in secondary prevention of cardiovascular events to aspirin. On the basis of this study we conducted a cost-effectiveness analysis from the perspective of Swiss third party payers. The following costs were included in the analysis: treatment costs of aspirin and clopidogrel, myocardial infarction, ischaemic stroke and primary non-fatal intracranial haemorrhage. For the calculation of the years of life gained the DEALE-method was applied. The net costs of treating 1000 patients, i.e. incremental drug costs less savings of treatment costs, are Fr. 1.5 Mio. The intervention with Clopidogrel lead to an additional gain of 63 life years in compared to aspirin. At additional yearly cost of Fr. 722.--per patient the analysis yield a cost-effectiveness of CHF 24,164 (nominal) Fr. 22,837 (discounted) per additional year of live saved. The results suggest that the cost-effectiveness of Clopidogrel in secondary prevention lie well within the range of other preventive cardiovascular interventions. Therefore, from an economic perspective the use of Clopidogrel in secondary prevention of major cardiovascular events in patients with atherosclerotic vascular disease is justifiable." @default.
- W2436692906 created "2016-06-24" @default.
- W2436692906 creator A5019496603 @default.
- W2436692906 creator A5062314601 @default.
- W2436692906 creator A5063369490 @default.
- W2436692906 date "2001-03-29" @default.
- W2436692906 modified "2023-09-25" @default.
- W2436692906 title "[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study]." @default.
- W2436692906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11550619" @default.
- W2436692906 hasPublicationYear "2001" @default.
- W2436692906 type Work @default.
- W2436692906 sameAs 2436692906 @default.
- W2436692906 citedByCount "5" @default.
- W2436692906 crossrefType "journal-article" @default.
- W2436692906 hasAuthorship W2436692906A5019496603 @default.
- W2436692906 hasAuthorship W2436692906A5062314601 @default.
- W2436692906 hasAuthorship W2436692906A5063369490 @default.
- W2436692906 hasConcept C112930515 @default.
- W2436692906 hasConcept C118552586 @default.
- W2436692906 hasConcept C126322002 @default.
- W2436692906 hasConcept C127413603 @default.
- W2436692906 hasConcept C127454912 @default.
- W2436692906 hasConcept C177713679 @default.
- W2436692906 hasConcept C18903297 @default.
- W2436692906 hasConcept C194828623 @default.
- W2436692906 hasConcept C27415008 @default.
- W2436692906 hasConcept C2777265216 @default.
- W2436692906 hasConcept C2777628954 @default.
- W2436692906 hasConcept C2777849778 @default.
- W2436692906 hasConcept C2780645631 @default.
- W2436692906 hasConcept C3019080777 @default.
- W2436692906 hasConcept C3019417119 @default.
- W2436692906 hasConcept C500558357 @default.
- W2436692906 hasConcept C515549039 @default.
- W2436692906 hasConcept C535046627 @default.
- W2436692906 hasConcept C71924100 @default.
- W2436692906 hasConcept C78519656 @default.
- W2436692906 hasConcept C86803240 @default.
- W2436692906 hasConceptScore W2436692906C112930515 @default.
- W2436692906 hasConceptScore W2436692906C118552586 @default.
- W2436692906 hasConceptScore W2436692906C126322002 @default.
- W2436692906 hasConceptScore W2436692906C127413603 @default.
- W2436692906 hasConceptScore W2436692906C127454912 @default.
- W2436692906 hasConceptScore W2436692906C177713679 @default.
- W2436692906 hasConceptScore W2436692906C18903297 @default.
- W2436692906 hasConceptScore W2436692906C194828623 @default.
- W2436692906 hasConceptScore W2436692906C27415008 @default.
- W2436692906 hasConceptScore W2436692906C2777265216 @default.
- W2436692906 hasConceptScore W2436692906C2777628954 @default.
- W2436692906 hasConceptScore W2436692906C2777849778 @default.
- W2436692906 hasConceptScore W2436692906C2780645631 @default.
- W2436692906 hasConceptScore W2436692906C3019080777 @default.
- W2436692906 hasConceptScore W2436692906C3019417119 @default.
- W2436692906 hasConceptScore W2436692906C500558357 @default.
- W2436692906 hasConceptScore W2436692906C515549039 @default.
- W2436692906 hasConceptScore W2436692906C535046627 @default.
- W2436692906 hasConceptScore W2436692906C71924100 @default.
- W2436692906 hasConceptScore W2436692906C78519656 @default.
- W2436692906 hasConceptScore W2436692906C86803240 @default.
- W2436692906 hasIssue "13" @default.
- W2436692906 hasLocation W24366929061 @default.
- W2436692906 hasOpenAccess W2436692906 @default.
- W2436692906 hasPrimaryLocation W24366929061 @default.
- W2436692906 hasRelatedWork W1584895772 @default.
- W2436692906 hasRelatedWork W2055646926 @default.
- W2436692906 hasRelatedWork W2086514840 @default.
- W2436692906 hasRelatedWork W2099734408 @default.
- W2436692906 hasRelatedWork W2133147248 @default.
- W2436692906 hasRelatedWork W2394052288 @default.
- W2436692906 hasRelatedWork W2436692906 @default.
- W2436692906 hasRelatedWork W2810872557 @default.
- W2436692906 hasRelatedWork W2990551121 @default.
- W2436692906 hasRelatedWork W655777636 @default.
- W2436692906 hasVolume "90" @default.
- W2436692906 isParatext "false" @default.
- W2436692906 isRetracted "false" @default.
- W2436692906 magId "2436692906" @default.
- W2436692906 workType "article" @default.